@article {KANEMURA3921, author = {YONEHIRO KANEMURA and MIHO SUMIDA and YOSHIKO OKITA and EMA YOSHIOKA and ATSUYO YAMAMOTO and DAISUKE KANEMATSU and YUKAKO HANDA and HAYATO FUKUSUMI and YUI INAZAWA and AI TAKADA and MASAHIRO NONAKA and SHIN NAKAJIMA and KANJI MORI and SHIGENORI GOTO and TAKASHI KAMIGAKI and TOMOKO SHOFUDA and SHUSUKE MORIUCHI and MAMI YAMASAKI}, title = {Systemic Intravenous Adoptive Transfer of Autologous Lymphokine-activated αβ T-Cells Improves Temozolomide-induced Lymphopenia in Patients with Glioma}, volume = {37}, number = {7}, pages = {3921--3932}, year = {2017}, publisher = {International Institute of Anticancer Research}, abstract = {In this clinical study, we investigated the safety and clinical usefulness of systemic adoptive immunotherapy using autologous lymphokine-activated αβ T-cells (αβ T-cells), combined with standard therapies, in patients with malignant brain tumors. Twenty-three patients with different malignant brain tumors, consisting of 14 treated with temozolomide (TMZ group) and 9 treated without temozolomide (non-TMZ group), received systemic intravenous injections of αβ T-cells (mean=10.4 injections/patient for the TMZ group, and 4.78 for the non-TMZ group). No significant adverse effects associated with the αβ T-cell injection were observed, and the total lymphocyte count (TLC) improved significantly in the TMZ group after five injections. Furthermore, CD8-positive or T-cell receptor V gamma -positive cells were increased with TLC in three patients with glioblastoma multiforme. These findings suggest that systemic αβ T-cell immunotherapy is well tolerated, and may help restore an impaired and imbalanced T-cell immune status, and temozolomide- and/or radiotherapy-induced lymphopenia. Future prospective study is needed to clarify the clinical merits of this immunotherapy.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/37/7/3921}, eprint = {https://ar.iiarjournals.org/content/37/7/3921.full.pdf}, journal = {Anticancer Research} }